5.51%
0.06%
1.50%
4.63%
45.88%
16.87%
80.89%
AI Spotlight on ALK
Company Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma.The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment.In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis.ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Market Data
| Last Price | 162.8 |
| Change Percentage | 5.51% |
| Open | 159.5 |
| Previous Close | 154.3 |
| Market Cap ( Millions) | 35677 |
| Volume | 312774 |
| Year High | 185.6 |
| Year Low | 110.2 |
| M A 50 | 156.52 |
| M A 200 | 157.75 |
Financial Ratios
| FCF Yield | 1.83% |
| Dividend Yield | 0.00% |
| ROE | 16.40% |
| Debt / Equity | 10.03% |
| Net Debt / EBIDTA | -3.44% |
| Price To Book | 6.79 |
| Price Earnings Ratio | 43.97 |
| Price To FCF | 54.72 |
| Price To sales | 6.63 |
| EV / EBITDA | 26.61 |
News
- Jan -30 - ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system
- Jan -22 - 3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%
- Dec -24 - 3 Stocks That May Be Trading Below Estimated Value
- Dec -20 - ALK – Financial calendar for the 2025 financial year
- Dec -18 - Positive results advance peanut tablet to phase II development
- Dec -12 - ACARIZAX® approved in Europe for treatment of young children
- Nov -27 - ALK’s pivotal phase 3 trial in children published in reputable scientific journal
- Nov -19 - Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins
- Nov -18 - 3 Stocks That May Be Trading At A Discount Of Up To 41.4%
- Nov -14 - Nine-month interim report (Q3) 2024 (unaudited)
- Nov -12 - ARS Pharmaceuticals announces agreement with ALK to commercialize neffy
- Nov -11 - ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
- Nov -09 - ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
- Nov -07 - Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
- Oct -09 - Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook
- Oct -07 - ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis
- Aug -22 - Six-month interim report (Q2) 2024
- Aug -22 - ALK upgrades its full-year revenue and earnings outlook
- Aug -14 - Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024
- Jun -21 - ALK upgrades its full-year revenue and earnings outlook
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Sublingual Immunotherapy-Tablets
Expected Growth : 10 %
What the company do ?
Sublingual Immunotherapy-Tablets from ALK-Abelló A/S is an allergy treatment that exposes patients to small amounts of allergens under the tongue to build tolerance.
Why we expect these perspectives ?
ALK-Abelló A/S's Sublingual Immunotherapy-Tablets growth is driven by increasing adoption in allergy treatment, rising prevalence of allergies, and growing demand for convenient, self-administered therapies. Expanding product offerings, strategic partnerships, and geographic expansion into new markets also contribute to the 10% growth.
Segment n°2 -> Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops
Expected Growth : 12 %
What the company do ?
Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops from ALK-Abelló A/S is a treatment for allergies, desensitizing patients to specific allergens, reducing symptoms over time.
Why we expect these perspectives ?
ALK-Abelló A/S's Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops growth is driven by increasing adoption in allergy treatment, rising prevalence of allergies, and growing demand for convenient and patient-friendly therapies. Additionally, expanding product offerings, strategic partnerships, and geographic expansion into emerging markets contribute to the 12% growth.
Segment n°3 -> Other
Expected Growth : 9 %
What the company do ?
ALK-Abelló A/S's Other segment includes revenue from out-licensing of intellectual property rights and royalties from partners.
Why we expect these perspectives ?
ALK-Abelló A/S's 9% growth is driven by increasing demand for allergy immunotherapy treatments, expansion into new markets, and strategic partnerships. The company's strong R&D pipeline, focus on digitalization, and cost-saving initiatives also contribute to its growth. Additionally, the rising prevalence of allergies and growing awareness of treatment options support the company's upward trend.
Alk-Abelló A/S Products
| Product Range | What is it ? |
|---|---|
| ACARIZAX | Acarizax is a sublingual allergy immunotherapy tablet for the treatment of house dust mite-induced allergic rhinitis. |
| GRAZAX | Grazax is a sublingual allergy immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis. |
| MITICURE | Miticure is a sublingual allergy immunotherapy tablet for the treatment of mite-induced allergic rhinitis. |
| RAGWITEK | Ragwitek is a sublingual allergy immunotherapy tablet for the treatment of ragweed pollen-induced allergic rhinitis. |
| ODACTRA | Odactra is a sublingual allergy immunotherapy tablet for the treatment of house dust mite-induced allergic rhinitis. |
ALK-Abelló A/S's Porter Forces
Threat Of Substitutes
ALK-Abelló A/S operates in a niche market with limited substitutes, but there are some alternatives available, which reduces the threat of substitutes.
Bargaining Power Of Customers
ALK-Abelló A/S has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
ALK-Abelló A/S relies on a few key suppliers for raw materials, which gives them some bargaining power. However, the company's size and reputation help to mitigate this risk.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs, which reduces the threat of new entrants.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players competing for market share. ALK-Abelló A/S operates in a niche market, but still faces intense competition from other companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 14.68% |
| Debt Cost | 3.95% |
| Equity Weight | 85.32% |
| Equity Cost | 6.04% |
| WACC | 5.73% |
| Leverage | 17.20% |
ALK-Abelló A/S : Quality Control
ALK-Abelló A/S passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| JAZZ | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of … |
| CAMX.ST | Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ALK-Abelló
A-Score
1-Year Total Return ->
🥈
Genmab
A-Score
1-Year Total Return ->
🥉
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
4
Camurus
A-Score
1-Year Total Return ->
5
Alkermes
A-Score
1-Year Total Return ->
6
